Ellen S Chan1, Alan L Landay, Todd T Brown, Heather J Ribaudo, Paria Mirmonsef, Igho Ofotokun, M Neale Weitzmann, Jeffrey Martinson, Karin L Klingman, Joseph J Eron, Carl J Fichtenbaum, Jill Plants, Babafemi O Taiwo. 1. aStatistical and Data Analysis Center, Harvard Chan School of Public Health, Boston, Massachusetts bDepartment of Immunology and Microbiology, Rush University Medical Center, Chicago, Illinois cDivision of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University, Baltimore, Maryland dDivision of Infectious Diseases eDivision of Endocrinology and Metabolism and Lipids, Emory University, Atlanta; Atlanta VA Medical Center, Decatur, Georgia fHIV Research Branch, Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland gDivision of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina hDivision of Infectious Diseases, University of Cincinnati, Cincinnati, Ohio iDivision of Infectious Diseases, Northwestern University, Chicago, Illinois, USA.
Abstract
OBJECTIVE: Studies exploring the immunologic effects of maraviroc (MVC) have produced mixed results; hence, it remains unclear whether MVC has unique immunologic effects in comparison with other antiretroviral drugs. We sought to determine whether MVC has differential effects compared with tenofovir disoproxil fumarate (TDF) during initial antiretroviral therapy. DESIGN: Prospective study in AIDS Clinical Trials Group A5303, a double-blind, placebo-controlled trial (N = 262) of MVC vs. TDF, each combined with boosted darunavir and emtricitabine. METHODS: A total of 31 cellular and soluble biomarkers were assayed at weeks 0 and 48. Polychromatic flow cytometry was performed on cryopreserved peripheral blood mononuclear cells. Soluble markers were assayed in plasma using ELISA kits. Analyses were as treated. RESULTS: Analyses included 230 participants (119 in MVC arm and 111 in TDF arm). Over 48 weeks of treatment, no significant differences were detected in declines in markers of inflammation and activation with MVC vs. TDF. A greater CD4 T-cell count increase (median +234 vs. +188 cells/μl, P = 0.036), a smaller CD8 T-cell count decrease (-6 vs. -109 cells/μl, P = 0.008), and a smaller CD4 : CD8 ratio increase (0.26 vs. 0.39, P = 0.003) occurred with MVC. Among participants with a baseline CD4 : CD8 ratio less than 1, a smaller proportion of MVC group normalized to a ratio greater than 1 at week 48 (15 and 36%, P < 0.001). CONCLUSION:MVC resulted in less improvement in the CD4 : CD8 ratio driven by greater increase in CD4 cell count but smaller decline in CD8 cell count. Changes in soluble or cellular biomarkers of inflammation and immune activation were not different between MVC and TDF.
RCT Entities:
OBJECTIVE: Studies exploring the immunologic effects of maraviroc (MVC) have produced mixed results; hence, it remains unclear whether MVC has unique immunologic effects in comparison with other antiretroviral drugs. We sought to determine whether MVC has differential effects compared with tenofovir disoproxil fumarate (TDF) during initial antiretroviral therapy. DESIGN: Prospective study in AIDS Clinical Trials Group A5303, a double-blind, placebo-controlled trial (N = 262) of MVC vs. TDF, each combined with boosted darunavir and emtricitabine. METHODS: A total of 31 cellular and soluble biomarkers were assayed at weeks 0 and 48. Polychromatic flow cytometry was performed on cryopreserved peripheral blood mononuclear cells. Soluble markers were assayed in plasma using ELISA kits. Analyses were as treated. RESULTS: Analyses included 230 participants (119 in MVC arm and 111 in TDF arm). Over 48 weeks of treatment, no significant differences were detected in declines in markers of inflammation and activation with MVC vs. TDF. A greater CD4 T-cell count increase (median +234 vs. +188 cells/μl, P = 0.036), a smaller CD8 T-cell count decrease (-6 vs. -109 cells/μl, P = 0.008), and a smaller CD4 : CD8 ratio increase (0.26 vs. 0.39, P = 0.003) occurred with MVC. Among participants with a baseline CD4 : CD8 ratio less than 1, a smaller proportion of MVC group normalized to a ratio greater than 1 at week 48 (15 and 36%, P < 0.001). CONCLUSION: MVC resulted in less improvement in the CD4 : CD8 ratio driven by greater increase in CD4 cell count but smaller decline in CD8 cell count. Changes in soluble or cellular biomarkers of inflammation and immune activation were not different between MVC and TDF.
Authors: Theodoros Kelesidis; Thuy Tien T Tran; James H Stein; Todd T Brown; Carlee Moser; Heather J Ribaudo; Michael P Dube; Robert Murphy; Otto O Yang; Judith S Currier; Grace A McComsey Journal: Clin Infect Dis Date: 2015-04-22 Impact factor: 9.079
Authors: Nikolas Itaru Wada; Lisa P Jacobson; Joseph B Margolick; Elizabeth Crabb Breen; Bernard Macatangay; Sudhir Penugonda; Otoniel Martínez-Maza; Jay H Bream Journal: AIDS Date: 2015-02-20 Impact factor: 4.177
Authors: Allan R Tenorio; Yu Zheng; Ronald J Bosch; Supriya Krishnan; Benigno Rodriguez; Peter W Hunt; Jill Plants; Arjun Seth; Cara C Wilson; Steven G Deeks; Michael M Lederman; Alan L Landay Journal: J Infect Dis Date: 2014-05-01 Impact factor: 5.226
Authors: Peter W Hunt; Nancy S Shulman; Timothy L Hayes; Viktor Dahl; Ma Somsouk; Nicholas T Funderburg; Bridget McLaughlin; Alan L Landay; Oluwatoyin Adeyemi; Lee E Gilman; Brian Clagett; Benigno Rodriguez; Jeffrey N Martin; Timothy W Schacker; Barbara L Shacklett; Sarah Palmer; Michael M Lederman; Steven G Deeks Journal: Blood Date: 2013-04-15 Impact factor: 22.113
Authors: Nicholas Funderburg; Magdalena Kalinowska; James Eason; James Goodrich; Jayvant Heera; Howard Mayer; Natasa Rajicic; Hernan Valdez; Michael M Lederman Journal: PLoS One Date: 2010-10-06 Impact factor: 3.240
Authors: F De Salvador-Guillouët; C Sakarovitch; J Durant; K Risso; E Demonchy; P M Roger; E Fontas Journal: PLoS One Date: 2015-10-20 Impact factor: 3.240
Authors: Gerd Fätkenheuer; Mark Nelson; Adriano Lazzarin; Irina Konourina; Andy I M Hoepelman; Harry Lampiris; Bernard Hirschel; Pablo Tebas; François Raffi; Benoit Trottier; Nicholaos Bellos; Michael Saag; David A Cooper; Mike Westby; Margaret Tawadrous; John F Sullivan; Caroline Ridgway; Michael W Dunne; Steve Felstead; Howard Mayer; Elna van der Ryst Journal: N Engl J Med Date: 2008-10-02 Impact factor: 176.079
Authors: Sergio Serrano-Villar; María Jesús Pérez-Elías; Fernando Dronda; José Luis Casado; Ana Moreno; Ana Royuela; José Antonio Pérez-Molina; Talia Sainz; Enrique Navas; José Manuel Hermida; Carmen Quereda; Santiago Moreno Journal: PLoS One Date: 2014-01-30 Impact factor: 3.240
Authors: Michael T Yin; Ellen S Chan; Todd T Brown; Jennifer Kinslow; Jeffrey Martinson; Alan Landay; Kathleen M Melbourne; Heather J Ribaudo; Edgar T Overton Journal: Antivir Ther Date: 2019